Investor Presentaiton
Cell Therapy Growth Spans the RMS Portfolio
-
Humanized and super-immunodeficient rodent models are critical for cell
therapy development and preclinical safety assessment
Many cell therapies are in the area of oncology, e.g. CAR-T therapies
Strong presence in the key Cambridge and South San Francisco biohubs
offering turnkey CRADLTM vivarium space
Attracting a range of biopharma companies – small and large
Additional synergies for CRADL TM from growing biotech clients providing new
business opportunities in the GEMS business
Additional synergies more broadly across CRL portfolio, particularly in DSA
Cell Solutions provides materials that are a critical foundation to support cell
therapy development process from research through commercialization
Illustrates the highly bespoke nature of the in vivo models that clients use in
their R&D programs
Charles River Laboratories (CRL)
9View entire presentation